Literature DB >> 15159277

Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Lavinia M Proctor1, Thiruma V Arumugam, Ian Shiels, Robert C Reid, David P Fairlie, Stephen M Taylor.   

Abstract

1. Complement activation is implicated in the pathogenesis of intestinal ischaemia-reperfusion injury (I/R), although the relative importance of individual complement components is unclear. A C3a receptor antagonist N(2)-[(2,2-diphenylethoxy)acetyl]-l-arginine (C3aRA) has been compared with a C5a receptor antagonist (C5aRA), AcF-[OPdChaWR], in a rat model of intestinal I/R. 2. C3aRA (IC(50)=0.15 microm) and C5aRA (IC(50)=0.32 microm) bound selectively to human polymorphonuclear leukocyte (PMN) C3a and C5a receptors, respectively. Effects on circulating neutrophils and blood pressure in the rat were also assessed. 3. Anaesthetised rats, subjected to intestinal ischaemia (30 min) and reperfusion (120 min), were administered intravenously with either (A) the C3aRA (0.1-1.0 mg x kg(-1)); the C5aRA (1.0 mg x kg(-1)); the C3aRA+C5aRA (each 1.0 mg x kg(-1)); or vehicle, 45 min prior, or (B) the C3aRA (1.0 mg x kg(-1)) or vehicle, 120 min prior to reperfusion. 4. The C3aRA and C5aRA, administered 45 min prior to reperfusion, displayed similar efficacies at ameliorating several disease markers (increased oedema, elevated ALT levels and mucosal damage) of rat intestinal I/R. The combination drug treatment did not result in greater injury reduction than either antagonist alone. However, doses of the C3aRA (0.01-10 mg x kg(-1)) caused transient neutropaenia, and the highest dose (10 mg x kg(-1)) also caused a rapid and transient hypertension. 5. The C3aRA (1.0 mg x kg(-1)), delivered 120 min prior to reperfusion to remove the global effect of C3aRA-induced neutrophil sequestration, did not attenuate the markers of intestinal I/R, despite persistent C3aR antagonism at this time. 6. C3aR antagonism does not appear to be responsible for the anti-inflammatory actions of this C3aRA in intestinal I/R in the rat. Instead, C3aRA-mediated global neutrophil tissue sequestration during ischaemia and early reperfusion may account for the protective effects observed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15159277      PMCID: PMC1575041          DOI: 10.1038/sj.bjp.0705819

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Intestinal ischemia-reperfusion and plasma enzyme levels.

Authors:  Fatma Cağlayan; Osman Cağlayan; Engin Gunel; Yesim Elcuman; Murat Cakmak
Journal:  Pediatr Surg Int       Date:  2002-05       Impact factor: 1.827

Review 2.  Complement in ischemia reperfusion injury.

Authors:  Niels C Riedemann; Peter A Ward
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

3.  A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats.

Authors:  Thiruma V Arumugam; Ian A Shiels; Anna J Strachan; Giovani Abbenante; David P Fairlie; Stephen M Taylor
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

4.  Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.

Authors:  A J Strachan; I A Shiels; R C Reid; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Protection of innate immunity by C5aR antagonist in septic mice.

Authors:  Markus S Huber-Lang; Niels C Riedeman; J Vidya Sarma; Ellen M Younkin; Stephanie R McGuire; Ines J Laudes; Kristina T Lu; Ren-Feng Guo; Thomas A Neff; Vaishalee A Padgaonkar; John D Lambris; L Spruce; D Mastellos; Firas S Zetoune; Peter A Ward
Journal:  FASEB J       Date:  2002-10       Impact factor: 5.191

6.  Intestinal and hemodynamic impairment following mesenteric ischemia/reperfusion.

Authors:  A Khanna; J E Rossman; H L Fung; M G Caty
Journal:  J Surg Res       Date:  2001-07       Impact factor: 2.192

7.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

Authors:  Tom Eirik Mollnes; Ole-Lars Brekke; Michael Fung; Hilde Fure; Dorte Christiansen; Grethe Bergseth; Vibeke Videm; Knut Tore Lappegård; Jörg Köhl; John D Lambris
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  A convergent solution-phase synthesis of the macrocycle Ac-Phe-[Orn-Pro-D-Cha-Trp-Arg], a potent new antiinflammatory drug.

Authors:  Robert C Reid; Giovanni Abbenante; Stephen M Taylor; David P Fairlie
Journal:  J Org Chem       Date:  2003-05-30       Impact factor: 4.354

9.  Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.

Authors:  Trent M Woodruff; Anna J Strachan; Nathan Dryburgh; Ian A Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  Arthritis Rheum       Date:  2002-09

10.  A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease.

Authors:  Trent M Woodruff; Thiruma V Arumugam; Ian A Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

View more
  33 in total

1.  Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats.

Authors:  Kathryn E Lillegard; Alex C Loeks-Johnson; Jonathan W Opacich; Jenna M Peterson; Ashley J Bauer; Barbara J Elmquist; Ronald R Regal; Jeffrey S Gilbert; Jean F Regal
Journal:  J Pharmacol Exp Ther       Date:  2014-08-22       Impact factor: 4.030

Review 2.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

3.  LPS preconditioning ameliorates intestinal injury in a rat model of hemorrhagic shock.

Authors:  Ruiming Chang; Yingyan Wang; Jianxing Chang; Liqiang Wen; Zhipeng Jiang; Tao Yang; Kai Yu
Journal:  Inflamm Res       Date:  2014-05-20       Impact factor: 4.575

Review 4.  The Complement System and Preeclampsia.

Authors:  Jean F Regal; Richard M Burwick; Sherry D Fleming
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

5.  Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.

Authors:  Carl Atkinson; Hongbin Song; Bo Lu; Fei Qiao; Tara A Burns; V Michael Holers; George C Tsokos; Stephen Tomlinson
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

Review 6.  The complement system and adverse pregnancy outcomes.

Authors:  Jean F Regal; Jeffrey S Gilbert; Richard M Burwick
Journal:  Mol Immunol       Date:  2015-03-21       Impact factor: 4.407

Review 7.  From apelin to exercise: emerging therapies for management of hypertension in pregnancy.

Authors:  Jeffrey S Gilbert
Journal:  Hypertens Res       Date:  2017-04-06       Impact factor: 3.872

8.  Role of the complement components C5 and C3a in a mouse model of myocardial ischemia and reperfusion injury.

Authors:  Marc N Busche; Gregory L Stahl
Journal:  Ger Med Sci       Date:  2010-09-08

9.  Elimination of C5aR prevents intestinal mucosal damage and attenuates neutrophil infiltration in local and remote organs.

Authors:  Da-Zhong Xu; Sergey B Zaets; Ruihua Chen; Qi Lu; Harini Rajan; Xiaoman Yang; John Zhang; Eleonora Feketova; Nancy Bogdan; Edwin A Deitch; Yang Cao
Journal:  Shock       Date:  2009-05       Impact factor: 3.454

10.  The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization.

Authors:  Mike C L Wu; Faith H Brennan; Jason P L Lynch; Susanna Mantovani; Simon Phipps; Rick A Wetsel; Marc J Ruitenberg; Stephen M Taylor; Trent M Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.